Andargie Yared, Sisay Woretaw, Molla Mulugeta, Tessema Getaye
School of Pharmacy, College of Medicine and Health Science, Debre Tabor University, Debre Tabor, Ethiopia.
Evid Based Complement Alternat Med. 2022 Jun 21;2022:4454881. doi: 10.1155/2022/4454881. eCollection 2022.
Conventional antidiabetic drugs are linked with a number of contraindications and untoward effects. The root decoction of L. has traditionally been used to treat diabetes. However, its safety and efficacy have not been scientifically authenticated yet. Hence, the study was conducted in mice to corroborate its antidiabetic potential and safety profile.
Using normoglycemic, oral glucose-loaded, and streptozotocin-induced diabetic mice models, the hypoglycemic and antihyperglycemic activities of 80% methanolic root extract were investigated. On streptozotocin-induced diabetic mice, the effect of the test extract on diabetic lipid profile and body weight was also investigated. Further, the in vitro -amylase inhibition activity was assessed.
The test extract was safe at a limit test dose of 2 g/kg. Dose-dependent -amylase inhibition activity was seen with peak percentage inhibition of 75.95% at 700 g/mL. In normoglycemic mice, the plant extract showed statistically significant hypoglycemic activity at 200 and 400 mg/kg ( < 0.001) at 6 h and 4 and 6 h of treatment, respectively; in oral glucose-loaded mice, at both the test doses, the glucose level was also significantly dropped at 120 ( < 0.01) and 60 and 120 min ( < 0.001), respectively; whereas, in the third model, the test extract showed significant antihyperglycemic activity at 100 mg/kg ( < 0.05) on the 14 day and at 200 ( < 0.01) and 400 mg/kg ( < 0.001) on the 7 and 14 day of treatment. Similarly, following repeated administration of the test extract at 200 and 400 mg/kg, the body weight was significantly improved on the 14 day ( < 0.05) and on the 7 and 14 day ( < 0.01), respectively, while diabetic dyslipidemia after 14 days ( < 0.05).
The study revealed that the test extract showed promising antihyperglycemic and antihyperlipidemic activity. Thus, the findings back up its use in Ethiopian remedies for diabetes.
传统抗糖尿病药物存在多种禁忌和不良反应。L. 的根煎剂传统上用于治疗糖尿病。然而，其安全性和有效性尚未得到科学验证。因此，本研究在小鼠中进行，以证实其抗糖尿病潜力和安全性。
使用血糖正常、口服葡萄糖负荷和链脲佐菌素诱导的糖尿病小鼠模型，研究了80%甲醇根提取物的降血糖和抗高血糖活性。在链脲佐菌素诱导的糖尿病小鼠上，还研究了受试提取物对糖尿病脂质谱和体重的影响。此外，评估了体外淀粉酶抑制活性。
受试提取物在2 g/kg的极限试验剂量下是安全的。观察到剂量依赖性淀粉酶抑制活性，在700 μg/mL时抑制率峰值为75.95%。在血糖正常的小鼠中，植物提取物在治疗6小时时200和400 mg/kg剂量下显示出统计学显著的降血糖活性（P<0.001），在口服葡萄糖负荷小鼠中，在两个试验剂量下，葡萄糖水平在120分钟时也显著下降（P<0.01）以及在60和120分钟时显著下降（P<0.001）；而在第三个模型中，受试提取物在治疗第14天时100 mg/kg剂量下显示出显著的抗高血糖活性（P<0.05），在第7天和第14天时200 mg/kg（P<0.01）和400 mg/kg（P<0.001）剂量下显示出显著的抗高血糖活性。同样，在200和400 mg/kg剂量下重复给予受试提取物后，体重在第14天（P<0.05）以及在第7天和第14天（P<0.01）时分别显著改善，而14天后糖尿病血脂异常（P<0.05）。
该研究表明受试提取物显示出有前景的抗高血糖和抗高血脂活性。因此，这些发现支持其在埃塞俄比亚糖尿病治疗中的应用。
